FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Para fins de pesquisa apenas. Leia o disclaimer completo →

Pesquisa/Paper
Voltar à Biblioteca de Pesquisa
PubMedReview

The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists.

Bendotti Giulia, Montefusco Laura, Lunati Maria Elena, Usuelli Vera, Pastore Ida, Lazzaroni Elisa, Assi Emma, Seelam Andy Joe, El Essawy Basset, Jang Jun
Pharmacological research2022DOI: 10.1016/j.phrs.2022.106320
GLP-1 Receptor Agonistsanti-inflammatory propertiesimmunological effects

Nota de Qualidade

7/10

Citações

0

Sujeitos

Não-Humanos

Análise da Peptide Contacts

Study Design

Review papers serve a critical role in synthesizing disparate findings into a coherent narrative. For rapidly evolving fields like peptide therapeutics, reviews help researchers and practitioners identify consensus and controversy.

Our Assessment

Quality Assessment: 7/10 — This is a solidly conducted study with clear methodology and reasonable conclusions. Minor limitations exist (noted below) but don't undermine the core findings. The evidence here is reliable enough to inform both research direction and practical decision-making.

Findings in Context

These findings advance our understanding of GLP-1 Receptor Agonists, anti-inflammatory properties, immunological effects in meaningful ways.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: Strong methodology makes this a valuable addition to the GLP-1 Receptor Agonists, anti-inflammatory properties, immunological effects evidence base. The findings here should inform future clinical trial design.

Encontros-chave

This review highlights the anti-inflammatory and immunomodulatory potential of GLP-1 receptor agonists, suggesting their broad spectrum of actions across various tissues.

Limitações

As a review paper, it relies on existing literature which may not cover all aspects or recent developments in the field. The conclusions are based on preclinical models and in vitro studies rather than clinical trials.

Como Interpretar Esta Pesquisa

1

Look for the sample size — larger studies produce more reliable results. Single-digit sample sizes warrant caution.

2

Check whether the study was funded by a pharmaceutical company or conducted independently, as funding sources can influence study design and reporting.

3

Reviews are only as good as the studies they include. Check whether the review examined study quality or simply tallied results.

4

Look for discussion of publication bias — studies with negative results are less likely to be published, which can skew review conclusions.

5

Always consult a qualified healthcare provider before making treatment decisions based on research findings. Published research is not a substitute for personalized medical advice.

Análise da Peptide Contacts

Exploring the emerging role of GLP-1 receptor agonists as potential anti-inflammatory agents and their implications for future therapeutic applications.

GLP-1 Receptor Agonistsanti-inflammatory propertiesimmunological effects

GLP-1 Receptor Agonists: A New Frontier in Anti-Inflammatory Therapy?

Published: May 17, 2026 | Source: Pharmacological research (2022) | Category: GLP-1 Receptor Agonists, anti-inflammatory properties, immunological effects

Overview

Recent research highlights the potential of Glucagon-Like Peptide-1 (GLP-1) receptor agonists as promising agents in reducing inflammation and modulating immune responses. This review by Bendotti et al., published in Pharmacological Research, underscores the broad spectrum of actions these peptides can have across various tissues, suggesting a new therapeutic avenue beyond their established roles in diabetes and obesity management.

Study Background

GLP-1 receptor agonists are well-known for their efficacy in lowering blood glucose levels and promoting weight loss. However, recent studies have begun to explore additional benefits of these compounds, particularly their anti-inflammatory properties and immunomodulatory effects. The review by Bendotti et al. synthesizes current evidence from preclinical models and in vitro studies to provide a comprehensive understanding of how GLP-1 receptor agonists might influence inflammatory responses.

What the Research Found

The review identifies several key mechanisms through which GLP-1 receptor agonists exert their anti-inflammatory effects:

  • Inhibition of pro-inflammatory cytokines: Studies show that GLP-1 receptor agonists can reduce levels of TNF-alpha and IL-6, two major mediators of inflammation.
  • Modulation of immune cell function: These peptides influence the activity of macrophages and T-cells, thereby altering inflammatory processes in tissues like adipose tissue and liver.
  • Regulation of oxidative stress: GLP-1 receptor agonists have been shown to mitigate oxidative stress-induced damage, which is a significant contributor to chronic inflammation.

What This Means for Peptide Users

While the primary use of GLP-1 receptor agonists remains in diabetes and obesity management, this review suggests that these peptides may offer additional benefits by reducing systemic inflammation. For individuals with conditions characterized by excessive inflammatory responses (such as autoimmune diseases or metabolic syndrome), GLP-1 receptor agonists might provide a novel therapeutic approach.

Limitations and Caveats

It is important to note that the findings presented in this review are primarily based on preclinical studies and in vitro experiments, which may not fully translate to clinical settings. Additionally, the review relies heavily on existing literature, potentially missing recent developments or emerging evidence. Clinical trials are necessary to confirm these preliminary observations.

How This Compares to Previous Research

Previous research has largely focused on the metabolic benefits of GLP-1 receptor agonists. The current review adds a new dimension by highlighting their anti-inflammatory and immunomodulatory properties. While some studies have hinted at these effects, this comprehensive analysis synthesizes existing data to provide a more robust understanding of the potential therapeutic applications.

Our Analysis

PeptideVault's assessment is that this review provides valuable insights into the multifaceted actions of GLP-1 receptor agonists beyond their established metabolic benefits. The identification of anti-inflammatory and immunomodulatory effects opens up new avenues for research and clinical application, though further investigation in human subjects is essential to validate these findings.

Key Takeaways

  • Emerging Role: GLP-1 receptor agonists may have significant anti-inflammatory properties.
  • Mechanistic Insights: The review outlines several mechanisms through which these peptides exert their effects on inflammation.
  • Future Directions: Clinical trials are necessary to confirm the potential therapeutic benefits of GLP-1 receptor agonists in inflammatory conditions.

Original Source

Citation: Bendotti Giulia, Montefusco Laura, Lunati Maria Elena et al. (2022). The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists.. Pharmacological research. DOI: 10.1016/j.phrs.2022.106320

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Nota do Editor

Esta análise foi escrita pela equipe de pesquisa da Peptide Contacts para tornar achados complexos acessíveis à comunidade de peptídeos. Encorajamos os leitores a revisar o paper original para metodologia e dados completos. Para mais sobre GLP-1 Receptor Agonists, explore nossas guias de pesquisa.

Citação

Bendotti Giulia, Montefusco Laura, Lunati Maria Elena et al.. (2022). The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists.. Pharmacological research. https://doi.org/10.1016/j.phrs.2022.106320

Visualize o texto completo em PubMed

Papers Relacionados

Explore Mais

Este conteúdo é derivado de pesquisas revisadas por pares para fins educativos apenas. Não constitui conselhos médicos. Sempre consulte um provedor de saúde qualificado antes de usar qualquer terapia baseada em peptídeos.